refixia
novo nordisk a/s - nonacog beta pegol - hemofilija b - antihemoraginiai - kraujavimo gydymas ir profilaktika pacientams, sergantiems hemofilija b (įgimtu ix faktoriaus trūkumu). , refixia can be used for all age groups.
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemoraginiai - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
betadine
lex ano, uab - povidonas, joduotas - tepalas - 100 mg/ml; 100 mg/g - povidone-iodine
betadine
limedika, uab - povidonas, joduotas - tepalas - 100 mg/g; 100 mg/ml - povidone-iodine
betadine
lex ano, uab - povidonas, joduotas - tepalas - 200 mg; 100 mg/g - povidone-iodine
betadine
adeofarma, uab - povidonas, joduotas - odos tirpalas - 100 mg/ml - povidone-iodine
betadine
tojaris projektai, uab - povidonas, joduotas - odos tirpalas - 100 mg/ml; 100 mg - povidone-iodine
betadine
tojaris projektai, uab - povidonas, joduotas - tepalas - 100 mg/g - povidone-iodine
betadine
actiofarma, uab - povidonas, joduotas - odos tirpalas - 100 mg/ml - povidone-iodine
betadine
lex ano, uab - povidonas, joduotas - odos tirpalas - 100 mg/ml - povidone-iodine